Clinical Trial 43588

Boston, MA 02114


Summary:

Study 43584 Flyer
If you or a family member have Recurrent Glioblastoma (rGBM) you may want to consider the Pro00077024 Phase 2 rGBM study.

What is the purpose of Pro00077024 Phase 2 rGBM study?


The purpose of this study is to examine the safety and efficacy of an investigational drug called PVSRIPO in people with a recurrence of their malignant glioma (brain tumor).

What is the investigational medication?

PVSRIPO is similar to the live poliovirus vaccine, which is given to children throughout the world for the prevention of poliomyelitis (polio). The poliovirus receptor (known as ‘Necl-5’) is abnormally expressed and found in malignant glioma cells. This means PVSRIPO can attach to and enter malignant glioma cells. Once inside, PVSRIPO can cause a range of irreversible changes that kill the cancer cells without affecting normal cells.

Who can participate in the Pro00077024 Phase 2 rGBM study?

You may be eligible to participate in the study if you:

  • Are ≥ 18 years of age at the time of entry into the study
  • Have experienced your first or second recurrence of GBM

How long is this study?

PVSRIPO is a one-time administration and study participation could last a year or more.


Clinical trials are medical research studies designed to test the safety and/or effectiveness of new investigational drugs, devices, or treatments in humans. These studies are conducted worldwide for a range of conditions and illnesses. Learn more about clinical research and participating in a study at About Clinical Trials.